Agios Pharmaceuticals Bolsa (NASDAQ: AGIO)

Últimas noticias sobre Agios Pharmaceuticals (NASDAQ:AGIO) Bolsa

AGIOS PHARMACEUTICALS INC

Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform and lowers the price target from $74 to $71.

News

Price Target

Analyst Ratings

AGIO

Scotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Lowers Price Target to $71

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) reported quarterly losses of $(1.55) per share which beat the analyst consensus estimate of $(1.80) by 13.89 percent. This is a 6.9 percent decrease over losses of $(1.45) per share from the same period last year. The company reported quarterly sales of $8.73 million which missed the analyst consensus estimate of $9.64 million by 9.48 percent. This is a 6.56 percent increase over sales of $8.19 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Agios Pharmaceuticals Q1 EPS $(1.55) Beats $(1.80) Estimate, Sales $8.73M Miss $9.64M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Agios Pharmaceuticals will report an earnings per share (EPS) of $-1.76.
The announcement from Agios Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.31, leading to a 0.24% drop in the share price on the subsequent day.
Here's a look at Agios Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.63</td>
<td>1.11</td>
<td>-1.59</td>
<td>-1.65</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.94</td>
<td>-1.43</td>
<td>-1.69</td>
<td>-1.45</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746036078_0.png" alt="eps graph" />
<h3>Performance of Agios Pharmaceuticals Shares</h3>
Shares of Agios Pharmaceuticals were trading at $29.1 as of April 29. Over the last 52-week period, shares are down 14.84%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Take on Agios Pharmaceuticals</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Agios Pharmaceuticals.
Analysts have given Agios Pharmaceuticals a total of 1 ratings, with the consensus rating being Buy. The average one-year price target is $58.0, indicating a potential 99.31% upside.
<h3>Comparing Ratings with Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Arcutis Biotherapeutics, Galapagos and Travere Therapeutics, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Arcutis Biotherapeutics, with an average 1-year price target of $19.12, suggesting a potential 34.3% downside.</li>
<li>Analysts currently favor an Underperform trajectory for Galapagos, with an average 1-year price target of $22.0, suggesting a potential 24.4% downside.</li>
<li>Analysts currently favor an Buy trajectory for Travere Therapeutics, with an average 1-year price target of $40.75, suggesting a potential 40.03% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
Within the peer analysis summary, vital metrics for Arcutis Biotherapeutics, Galapagos and Travere Therapeutics are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agios Pharmaceuticals</td>
<td>Buy</td>
<td>51.06%</td>
<td>$9.47M</td>
<td>-6.09%</td>
</tr>
<tr>
<td>Arcutis Biotherapeutics</td>
<td>Buy</td>
<td>427.58%</td>
<td>$64.45M</td>
<td>-6.87%</td>
</tr>
<tr>
<td>Galapagos</td>
<td>Underperform</td>
<td>20.09%</td>
<td>$61.25M</td>
<td>-5.44%</td>
</tr>
<tr>
<td>Travere Therapeutics</td>
<td>Buy</td>
<td>65.98%</td>
<td>$72.23M</td>
<td>-421.09%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Agios Pharmaceuticals ranks at the bottom for Revenue Growth and Gross Profit among its peers. It also has the lowest Return on Equity.
<h3>Get to Know Agios Pharmaceuticals Better</h3>
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
<h3>Agios Pharmaceuticals: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Agios Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 51.06% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Agios Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -899.56%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Agios Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.09% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -5.59%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.04, Agios Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/AGIO/earnings">To track all earnings releases for Agios Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Agios Pharmaceuticals's Earnings

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Buy and maintains $58 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Agios Pharmaceuticals, Maintains $58 Price Target

On Thursday, Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to &lt;18 years with PK deficiency who are not regularly transfused achieved its primary <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43687696/agios-phase-3-activate-kids-study-of-mitapivat-in-children-with-pyruvate-kinase-pk-deficiency-not-" rel="noreferrer noopener">endpoint of hemoglobin response</a>.
Pyruvate kinase (PK) deficiency is&nbsp;a rare, inherited disorder that affects red blood cells.
The safety results were consistent with the safety profile for mitapivat previously observed for adult patients with PK deficiency who are not regularly transfused.
The study&#8217;s primary endpoint was hemoglobin response, defined as a ≥1.5 g/dL ​increase in hemoglobin concentration from baseline ​ sustained at two or more scheduled assessments at​ Weeks 12, 16, and 20.
<ul>
<li>In addition, the pre-specified supportive analysis based on traditional methodology comparing the hemoglobin response rate for mitapivat versus placebo provided further evidence that the primary endpoint was met.</li>
<li>31.6% (6/19) of patients in the mitapivat arm achieved a hemoglobin response compared to 0% (0/11) of patients in the placebo arm; the 95% confidence interval for the difference in hemoglobin response rates between mitapivat and placebo was >0 (95% CI=10.8% to 52.7%). </li>
<li>In addition, improvements in changes from baseline for markers of hemolysis (indirect bilirubin, lactate dehydrogenase and haptoglobin) were observed in the mitapivat arm compared to the placebo arm.</li>
</ul>
In August 2024, Agios reported topline results from the&nbsp;ACTIVATE-KidsT Phase 3 study&nbsp;of mitapivat in children aged 1 to &lt;18 years with PK deficiency <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40110159/agios-pharmaceuticals-rare-blood-disorder-drug-misses-primary-goal-in-pediatric-study-stock-slide" rel="noreferrer noopener">who are regularly transfused</a>.
<ul>
<li>In the ACTIVATE-KidsT study, 28.1% of patients in the mitapivat arm achieved the primary endpoint of transfusion reduction response, compared to 11.8% of patients in the placebo arm.</li>
<li>Transfusion-free and normal hemoglobin response were secondary endpoints in this study and were only observed in patients in the mitapivat arm.</li>
</ul>
Based on the clinically meaningful results observed in both the ACTIVATE-Kids and ACTIVATE-KidsT Phase 3 studies, Agios intends to submit a marketing application for mitapivat in pediatric patients with PK deficiency.
Concurrently, the company reported fourth-quarter Pyrukynd&nbsp;revenues of $10.7 million, up 20% sequentially, beating the consensus of $9.33 million. 223 unique patients have completed prescription enrollment forms, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43687726/agios-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-highlights" rel="noreferrer noopener">up 6% sequentially</a>.
A total of 130 patients are on PYRUKYND therapy, inclusive of new prescriptions and continued therapy.
Cash, cash equivalents, and marketable securities as of December 31, 2024, were $1.5 billion.
Price Action: AGIO stock is down 1.86% at $32.20 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43691982/iron-mountain-q4-earnings-storage-and-data-center-revenue-growth-dividend-climbs-10-strong-2025-outlook" target="_blank" rel="noreferrer noopener">Iron Mountain Q4 Earnings: Storage And Data Center Revenue Growth, Dividend Climbs 10%, Strong 2025 Outlook</a></li>
</ul>

Biotech

Health Care

General

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

Agios Pharmaceuticals Q4 Sales $10.70M Beat $9.33M Estimate, Net Loss Of $96.5M Vs. $95.9M YoY, Cash Balance Of $1.5B

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) reported quarterly earnings of $11.64 per share which beat the analyst consensus estimate of $11.46 by 1.57 percent. This is a 283.89 percent increase over losses of $(6.33) per share from the same period last year. The company reported quarterly sales of $36.50 million which beat the analyst consensus estimate of $35.13 million by 3.90 percent. This is a 36.07 percent increase over sales of $26.82 million the same period last year.

Agios Pharmaceuticals FY 2024 GAAP EPS $11.64 Beats $11.46 Estimate, Sales $36.50M Beat $35.13M Estimate

Agios Says ACTIVATE-Kids Phase 3 Study Of Mitapivat Met Primary Endpoint

AENT

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COIN

CROX

CYBR

DDOG

DKNG

DNOW

EEFT

EGAN

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

Agios Reveals Anticipated Key 2025 Milestones And Value-driving Catalysts Through 2026

The review classification for this application is Standard and the Prescription Drug User Fee Act (PDUFA) goal date is September 7, 2025.

Agios Pharmaceuticals Says FDA Accepted sNDA For PYRUKYND (Mitapivat) For Treatment Of Adult Patients With Non-Transfusion-Dependent And Transfusion-Dependent Alpha- Or Beta-thalassemia

Agios Pharmaceuticals Filing Reported FDA Approved Update To PYRUKYND For Hemolytic Anemia In Adults With Pyruvate Kinase Deficiency; US Prescribing Info Revised To Include Liver Injury Risk

Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) from Overweight to Overweight.

Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticalsto Overweight

. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease.

The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply during Monday's session after Wedbush maintained an Outperform rating on the stock and raised its price target <a href="https://www.benzinga.com/markets/equities/24/12/42505310/tesla-prepares-for-holiday-rush-tapping-into-global-supercharger-demand-to-drive-revenue-growth">from $400 to $515</a>.
Tesla shares gained 5% to $458.08 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares gained 59.6% to $1.5000.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares jumped 42.4% to $9.49.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) climbed 31.8% to $2.6950.</li>
<li>Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) gained 31.8% to $23.53 after the company announced Phase 3 results for its thyroid eye disease treatment trial.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) rose 25.5% to $8.99.</li>
<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) gained 24.7% to $34.45 after the company reported topline results from its Phase 2 CANYON trial of Sevasemten in individuals with Becker muscular dystrophy, with the trial meeting its primary endpoint.</li>
<li>Aehr Test Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) rose 24.2% to $14.32 after the company announced it secured a $10 million order for AI semiconductor testing.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) climbed 19.8% to $25.08. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) gained 18.4% to $7.26. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) rose 15.5% to $8.14. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) gained 13.4% to $30.99. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) gained 10.5% to $25.11. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Asana, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NASDAQ">ASAN</a>) gained 9.5% to $26.45.</li>
<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) surged 9.1% to $42.54.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) surged 7.6% to $242.06 on continued momentum from last week after the company reported earnings for the fourth-quarter.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) gained 7% to $109.62.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42507587/tesla-to-rally-around-18-here-are-10-top-analyst-forecasts-for-monday">Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

Intraday Update

Markets

Movers

AEHR

ASAN

AVGO

BTDR

CIFR

EWTX

MARA

QUBT

RGTI

SGMO

TSLA

VRDN

WULF

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday

8 analysts have shared their evaluations of Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $56.62, a high estimate of $75.00, and a low estimate of $51.00. This current average reflects an increase of 3.26% from the previous average price target of $54.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1733850120_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Agios Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$75.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$53.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Agios Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Agios Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Agios Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Agios Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AGIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Agios Pharmaceuticals analyst ratings.</a>
<h2>About Agios Pharmaceuticals</h2>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Key Indicators: Agios Pharmaceuticals's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Agios Pharmaceuticals displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 21.15%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10574.69%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 82.89%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Agios Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 73.92%. This signifies efficient management of assets and strong financial health.
Debt Management: Agios Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Agios Pharmaceuticals

RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and raises the price target from $55 to $57.

RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $57

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform and raises the price target from $53 to $75.

Scotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Raises Price Target to $75

Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today presented positive results from the Phase 3 ENERGIZE-T study investigating mitapivat, an oral, small molecule PK activator, in adults with transfusion-dependent alpha- or beta-thalassemia. These findings were shared in an oral presentation (abstract #409) at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
In the ENERGIZE-T trial, mitapivat demonstrated a statistically significant reduction in transfusion burden compared to placebo in patients with transfusion-dependent alpha- or beta-thalassemia, achieving its primary endpoint. Additionally, the ENERGIZE-T study met all the key secondary endpoints, with mitapivat demonstrating a statistically significant reduction in additional measures of transfusion reduction response compared to placebo. In June 2024, Agios also <a href="https://www.globenewswire.com/Tracker?data=yCZIHDR8PSvrAcYmrbhYVzXtz0qOrlBEmNLt7nN_xw6pl1Mj2AXdoy1h6DGsnSHtC9uUFdnfS-kmUwx8-iSnaOJkdU3hjhRmj1SJM6ZrLFO6iwRjg8fcimCj7_cSLjAcTUnWPq0clc5THhnffh8TSuew3ZJSODjBe9FO6EN8DPbro4Y_f9jLQwMPuUlNC79JIOX2IXMP3L7atf5mK8ExdWvum1h8-Fgpguku085aOMQ=">presented positive results</a> from the Phase 3 ENERGIZE study, which evaluated mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia.

Agios Presented At ASH, Results From Phase 3 ENERGIZE-T Study of Mitapivat; Study Achieved Primary, All Key Secondary Endpoints In Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia

Press Releases

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios to Present at the TD Cowen 45th Annual Healthcare Conference  on March 3, 2025

Agios to Present at Upcoming Investor Conferences

Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

Comments

Agios Pharmaceuticals

Noticias

Últimas noticias sobre Agios Pharmaceuticals (NASDAQ:AGIO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL